Research programme: heparanase inhibitors - TBG Diagnostics Limited

Drug Profile

Research programme: heparanase inhibitors - TBG Diagnostics Limited

Alternative Names: PG 500 series; PG 562

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Progen Pharmaceuticals
  • Developer Griffith University; Progen Pharmaceuticals Limited
  • Class Oligosaccharides; Proteoglycans; Small molecules
  • Mechanism of Action Heparanase inhibitors; Intercellular signalling peptide and protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Inflammation
  • Discontinued Asthma; Autoimmune disorders; Inflammatory bowel diseases; Multiple sclerosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Australia (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Australia (PO)
  • 15 Jul 2010 Preclinical trials in Cancer in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top